Evanthia T Roussos Torres, Won J Ho, Ludmila Danilova, Joseph A Tandurella, James Leatherman, Christine Rafie, Chenguang Wang, Adam Brufsky, Patricia LoRusso, Vincent Chung, Yuan Yuan, Melinda Downs, Ashley O'Connor, Sarah M Shin, Alexei Hernandez, Elizabeth L Engle, Richard Piekarz, Howard Streicher, Zahra Talebi, Michelle A Rudek, Qingfeng Zhu, Robert A Anders, Ashley Cimino-Mathews, Elana J Fertig, Elizabeth M Jaffee, Vered Stearns, Roisin M Connolly
We report the results of 24 women, 50% (N = 12) with hormone receptor-positive breast cancer and 50% (N = 12) with advanced triple-negative breast cancer, treated with entinostat + nivolumab + ipilimumab from the dose escalation (N = 6) and expansion cohort (N = 18) of ETCTN-9844 ( NCT02453620 ). The primary endpoint was safety. Secondary endpoints were overall response rate, clinical benefit rate, progression-free survival and change in tumor CD8:FoxP3 ratio...
February 14, 2024: Nature Cancer